Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 8/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935333 | 0.87 | MAPK1 (0.44) | MAPK1KMT2APKML3MBTL1GLA | |
| SCHEMBL12012193 | 0.83 | ALDH1A1 (0.52) | MAPK1KMT2APKML3MBTL1GLA | |
| SCHEMBL3237884 | 0.83 | USP2 (0.41) | KMT2AMAPTBDKRB1ALDH1A1 | |
| SCHEMBL2236762 | 0.82 | MAPK1 (0.50) | MAPK1KMT2APKML3MBTL1GLA | |
| SCHEMBL3443096 | 0.82 | KEAP1 (0.49) | MAPK1KMT2AL3MBTL1BDKRB1KEAP1 | |
| SCHEMBL3440259 | 0.81 | PKM (0.49) | MAPK1KMT2APKML3MBTL1GLA | |
| SCHEMBL12010517 | 0.81 | PKM (0.51) | MAPK1KMT2APKML3MBTL1GLA | |
| SCHEMBL2237548 | 0.80 | MAPK1 (0.47) | MAPK1KMT2APKMBDKRB1 | |
| SCHEMBL15514172 | 0.79 | KMT2A (0.43) | MAPK1KMT2APKML3MBTL1GLA | |
| SCHEMBL1935336 | 0.79 | BDKRB1 (0.41) | MAPK1KMT2APKMBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | MAPK1 625/4885KMT2A 1859/4885PKM 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.